ClinicalTrials.gg
CompletedNCT01488019Updated Jun 12, 2017Results posted

Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

A Phase 4 interventional study of Perforomist-Placebo and Perforomist, nebulization, COPD in COPD, sponsored by Dey. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by Dey (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,071
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
17th of 89
1,071 · median 120
Started
2012
with 2 others
Phase 4
26 of 89
2 open now
Registered
42nd of 89
by date
Lead sponsor
11 of 89
Dey

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 3 that started in 2012, is one of 26 in phase 4, and was the 42nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.

Read the detailed description

None provided.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand the study requirements, provide written , and agree to abide by the study protocol and its restrictions
  2. Male and female subjects at least 40 years of age with a medical diagnosis of (i.e. persistent presence of dyspnea, cough or sputum production and a history of exposure to risk factors for the disease, such as tobacco smoke)
  3. A current or prior history of at least 10 pack-years of cigarette smoking and a baseline breathlessness severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at randomization.
  4. Women of (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study by using adequate at study entry and throughout the trial. WOCBP will be advised to notify the Investigator of any change in their pregnancy status. WOCBP include: any female who has experienced menarche and is not (defined as amenorrhea for at least 12 consecutive months), or has not undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Women who are using acceptable contraceptive medications or devices to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be considered WOCBP.
  5. Able to complete all aspects of the study through the end of the study, including all visits and tests, and self-administration of study medications.

Exclusion criteria

Exclusion Criteria:

  1. A medical diagnosis of asthma. Indication of a past history of asthma that is deemed inaccurate to a subject's current condition by the Investigator must be adequately addressed in the medical history.
  2. abnormal chest x-ray (CXR) (within the past 12 months) diagnostic of active/significant disease other than .
  3. Evidence of any unstable or clinically significant hematopoietic, malignant, cardiovascular, hepatic, renal, neurologic, psychiatric, disorder, or condition or disease other than COPD that, in the opinion of the Investigator, could place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives.
  4. Subjects who had radiation or chemotherapy within the previous 12 months.
  5. An abnormal laboratory test at screening deemed clinically significant and exclusionary by the Investigator.
  6. A history of to study drugs or their components, including albuterol rescue.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,071 participants (actual)

Study arms

  • Experimental
    Perforomist, nebulization, COPD

    Active

    Drug: Perforomist, nebulization, COPD

  • Placebo comparator
    Perforomist-Placebo

    Placebo

    Drug: Perforomist-Placebo

Interventions

  • DrugPerforomist-Placebo

    Placebo vehicle, 2mL, twice daily for 52 weeks

    Also known as: Perforomist

  • Perforomist, 20 mcg/2 mL, twice daily for 52 weeks

    Also known as: Formoterol fumarate

06

What researchers measure

Primary outcomes

  1. Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation

    The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.

    Time frame: 0 to 52 weeks

  2. Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks

    The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.

    Time frame: 0 to 52 weeks

Secondary outcomes

  1. Summary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality

    An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.

    Time frame: 0 to 52 weeks

  2. Individual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization

    Time frame: 0 to 52 weeks

  3. Number of Subjects With Protocol-Defined COPD Exacerbation

    COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.

    Time frame: 0 to 52 weeks

  4. Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks

    COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.

    Time frame: 0 to 52 weeks

  5. FEV1 Changes From Baseline at Months 3, 6, 9 and 12

    Time frame: On treatment at months 3, 6, 9 and 12

  6. FVC Changes From Baseline at Months 3, 6, 9 and 12

    Time frame: On treatment at months 3, 6, 9 and 12

  7. IC Changes From Baseline at Months 3, 6, 9 and 12

    Time frame: On treatment at months 3, 6, 9 and 12

  8. Saint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12

    Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either "yes" or "no". Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.

    Time frame: On treatment at months 3, 6, 9 and 12

  9. Transition Dyspnea Index

    The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.

    Time frame: On treatment at months 3, 6, 9 and 12

  10. Health Care Utilization and Economic Impact - Number of Emergency Department Visits

    Time frame: 0 to 52 weeks

  11. Summary of Subjects Requiring Intubation or Non-Invasive Ventilation

    Time frame: 0 to 52 weeks

  12. Rescue Medication Usage

    Number of puffs of rescue medication (albuterol pMDI) used per day

    Time frame: 0 to 52 weeks

07

Results

Posted Jun 12, 2017

Participant flow

Participant flow — Overall Study
MilestonePerforomist Inhalation SolutionMatching Placebo
Started541530
Completed294226
Not completed247304

Outcome measures

PrimaryNumber of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation

The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.

Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation
ParticipantsPerforomist Inhalation SolutionMatching Placebo
Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation6457
Statistical analysis
  • Perforomist Inhalation Solution vs Matching Placebo · Regression, Cox · Hazard ratio (hr): 0.965 · 90% CI 0.711 to 1.308Hazard Ratio was calculated as Perforomist Inhalation Solution vs Placebo. The non-inferiority margin for the hazard ratio is 1.5.
PrimaryKaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks

The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.

Time frame:
0 to 52 weeks
Reported as:
Number · percent
Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks
percentPerforomist Inhalation SolutionMatching Placebo
Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks15.514.9
SecondarySummary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality

An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.

Time frame:
0 to 52 weeks
Reported as:
Number · Participants
Summary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality
ParticipantsPerforomist Inhalation SolutionMatching Placebo
Incidence of All Cause Mortalities310
Incidence of Respiratory Related Mortalities01
Incidence of COPD Related Mortalities01
SecondaryIndividual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization
Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Individual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization
ParticipantsPerforomist Inhalation SolutionMatching Placebo
Subjects with a COPD- related ER Visit4647
Subjects with a COPD-Related Hospitalization3943
SecondaryNumber of Subjects With Protocol-Defined COPD Exacerbation

COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.

Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Number of Subjects With Protocol-Defined COPD Exacerbation
ParticipantsPerforomist Inhalation SolutionMatching Placebo
Number of Subjects With Protocol-Defined COPD Exacerbation142135
SecondaryKaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks

COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.

Time frame:
0 to 52 weeks
Reported as:
Number · percent
Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks
percentPerforomist Inhalation SolutionMatching Placebo
Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks34.734.0
SecondaryFEV1 Changes From Baseline at Months 3, 6, 9 and 12
Time frame:
On treatment at months 3, 6, 9 and 12
Reported as:
Least squares mean · Litres
FEV1 Changes From Baseline at Months 3, 6, 9 and 12
LitresPerforomist Inhalation SolutionMatching Placebo
Change from Baseline FEV1: Month 30.058 ± 0.01160.016 ± 0.0123
Change from Baseline FEV1: Month 60.057 ± 0.01300.017 ± 0.0143
Change from Baseline FEV1: Month 90.050 ± 0.01360.029 ± 0.0151
Change from Baseline FEV1: Month 120.030 ± 0.01440.000 ± 0.0160
SecondaryFVC Changes From Baseline at Months 3, 6, 9 and 12
Time frame:
On treatment at months 3, 6, 9 and 12
Reported as:
Mean · Litres
FVC Changes From Baseline at Months 3, 6, 9 and 12
LitresPerforomist Inhalation SolutionMatching Placebo
Change from Baseline FVC: Month 30.1051 ± 0.404790.0062 ± 0.38724
Change from Baseline FVC: Month 60.1006 ± 0.38875-0.0241 ± 0.37124
Change from Baseline FVC: Month 90.1009 ± 0.39533-0.0254 ± 0.40947
Change from Baseline FVC: Month 120.0645 ± 0.43490-0.0581 ± 0.38069
SecondaryIC Changes From Baseline at Months 3, 6, 9 and 12
Time frame:
On treatment at months 3, 6, 9 and 12
Reported as:
Mean · Litres
IC Changes From Baseline at Months 3, 6, 9 and 12
LitresPerforomist Inhalation SolutionMatching Placebo
Change from Baseline IC: Month 30.0287 ± 0.42478-0.0119 ± 0.39505
Change from Baseline IC: Month 60.0440 ± 0.44862-0.0106 ± 0.43483
Change from Baseline IC: Month 90.1584 ± 1.84290-0.0118 ± 0.43513
Change from Baseline IC: Month 120.0477 ± 0.48057-0.0105 ± 0.44289
SecondarySaint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12

Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either "yes" or "no". Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.

Time frame:
On treatment at months 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Saint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12
units on a scalePerforomist Inhalation SolutionMatching Placebo
Change from Baseline SGRQ Total Score: Month 3-3.252 ± 0.5472-2.027 ± 0.5727
Change from Baseline SGRQ Total Score: Month 6-2.329 ± 0.6541-2.511 ± 0.7156
Change from Baseline SGRQ Total Score: Month 9-2.021 ± 0.7022-2.115 ± 0.7681
Change from Baseline SGRQ Total Score: Month 12-1.453 ± 0.7559-1.475 ± 0.8345
SecondaryTransition Dyspnea Index

The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.

Time frame:
On treatment at months 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Transition Dyspnea Index
units on a scalePerforomist Inhalation SolutionMatching Placebo
Month 30.7 ± 0.110.0 ± 0.12
Month 60.5 ± 0.130.4 ± 0.14
Month 90.7 ± 0.140.4 ± 0.15
Month 120.5 ± 0.140.6 ± 0.16
SecondaryHealth Care Utilization and Economic Impact - Number of Emergency Department Visits
Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Health Care Utilization and Economic Impact - Number of Emergency Department Visits
ParticipantsPerforomist Inhalation SolutionMatching Placebo
0447437
17875
21516
>=312
SecondarySummary of Subjects Requiring Intubation or Non-Invasive Ventilation
Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Summary of Subjects Requiring Intubation or Non-Invasive Ventilation
ParticipantsPerforomist Inhalation SolutionMatching Placebo
Summary of Subjects Requiring Intubation or Non-Invasive Ventilation310
SecondaryRescue Medication Usage

Number of puffs of rescue medication (albuterol pMDI) used per day

Time frame:
0 to 52 weeks
Reported as:
Mean · Mean Puffs per Day
Rescue Medication Usage
Mean Puffs per DayPerforomist Inhalation SolutionMatching Placebo
Baseline2.55 ± 2.4962.52 ± 2.484
Treatment Phase1.92 ± 2.0632.35 ± 2.521

Adverse events

Collected over Approximately 14 months (date of signature of the Informed Consent Form to 30 days after last dose of study drug). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Perforomist Inhalation Solution3/541 (0.6%)86/541 (15.9%)374/541 (69.1%)
Matching Placebo10/530 (1.9%)85/530 (16%)369/530 (69.6%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
EventPerforomist Inhalation SolutionMatching Placebo
COPDRespiratory, thoracic and mediastinal disorders39/54140/530
PneumoniaInfections and infestations10/54110/530
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders6/5416/530
Acute Myocardial InfarctionCardiac disorders2/5416/530
Lobar PneumoniaInfections and infestations2/5416/530
SepsisInfections and infestations2/5414/530
Renal failure acuteRenal and urinary disorders1/5414/530
Coronary artery diseaseCardiac disorders3/5413/530
Cardiac arrestCardiac disorders1/5413/530
Cardiac failure congestiveCardiac disorders1/5413/530
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPerforomist Inhalation SolutionMatching Placebo
COPDRespiratory, thoracic and mediastinal disorders164/541145/530
DyspneaRespiratory, thoracic and mediastinal disorders35/54140/530
CoughRespiratory, thoracic and mediastinal disorders39/54124/530
Upper Respiratory Tract InfectionInfections and infestations36/54132/530
BronchitisInfections and infestations34/54126/530
SinusitisInfections and infestations25/54112/530
NasopharyngitisInfections and infestations24/54118/530
HeadacheNervous system disorders21/54122/530
PneumoniaInfections and infestations18/54118/530
NauseaGastrointestinal disorders18/5417/530

Baseline characteristics

Safety Set

Age, Continuous
Age, Continuous(years)Perforomist Inhalation SolutionMatching PlaceboTotal
Mean62.7 ± 9.0162.5 ± 9.1762.6 ± 9.09
Sex: Female, Male
Sex: Female, Male(Participants)Perforomist Inhalation SolutionMatching PlaceboTotal
Female285267552
Male256263519
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Perforomist Inhalation SolutionMatching PlaceboTotal
Hispanic or Latino292655
Not Hispanic or Latino5125041016
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Perforomist Inhalation SolutionMatching PlaceboTotal
White483478961
Black or African American514697
American Indian or Alaska Native022
Asian or Pacific Islander415
Other336
Region of Enrollment
Region of Enrollment(Participants)Perforomist Inhalation SolutionMatching PlaceboTotal
United States5415301071
Screening COPD Severity (GOLD) n (%)
Screening COPD Severity (GOLD) n (%)(Participants)Perforomist Inhalation SolutionMatching PlaceboTotal
Moderate (% Predicted FEV1 50 to <80%)274273547
Severe (% Predicted FEV1 30 to <50%)261250511
Very Severe (% Predicted FEV1 <30%)347
Not Reported/Unknown336
Baseline FEV1
Baseline FEV1(Litres)Perforomist Inhalation SolutionMatching PlaceboTotal
Mean1.2494 ± 0.475931.2926 ± 0.504961.2707 ± 0.49073
Baseline % Predicted FEV1
Baseline % Predicted FEV1(%)Perforomist Inhalation SolutionMatching PlaceboTotal
Mean43.82 ± 12.64644.89 ± 13.78744.35 ± 13.226

7 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Chandar Abboy
    Greenville, South Carolina 29615, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2011
First posted
Dec 8, 2011
Start
Mar 2012
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Jun 12, 2017
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01488019
Lead sponsor
Dey
Responsible party
Sponsor
First posted
Dec 8, 2011
Start date
Mar 2012
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Jun 12, 2017
Last update
Jun 12, 2017

Study contacts

Dik Ng
study director · Mylan Pharma UK Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion